• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Biologic Therapy in COVID-19.COVID-19中的生物疗法。
Arch Bronconeumol. 2021 Jan;57:1-2. doi: 10.1016/j.arbres.2020.06.007. Epub 2020 Jun 26.
2
Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).新型冠状病毒肺炎（COVID-19）与银屑病的生物治疗：两例严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者成功康复
Dermatol Ther (Heidelb). 2020 Aug;10(4):881-885. doi: 10.1007/s13555-020-00394-8. Epub 2020 May 29.
3
How lockdown measures, during COVID-19 pandemic, matter on psoriatic patient's perception: Study on 600 patients on biologic therapy.疫情封锁措施如何影响银屑病患者的认知：600 名生物治疗患者的研究。
J Infect Public Health. 2021 Jul;14(7):878-882. doi: 10.1016/j.jiph.2021.03.010. Epub 2021 Apr 1.
4
Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].严重急性呼吸综合征冠状病毒 2 与银屑病患者生物制剂的使用 [公式：见正文]。
J Cutan Med Surg. 2020 Nov/Dec;24(6):625-632. doi: 10.1177/1203475420945234. Epub 2020 Aug 6.
5
Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.COVID-19 大流行期间生物治疗的银屑病患者监测：单中心经验。
Dermatol Ther. 2021 Jan;34(1):e14700. doi: 10.1111/dth.14700. Epub 2020 Dec 28.
6
Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.生物治疗的炎症性肠病患者中 SARS-CoV2 的血清阳性率。
J Crohns Colitis. 2021 May 4;15(5):864-868. doi: 10.1093/ecco-jcc/jjaa237.
7
Psoriasis, biologic therapy, and the pandemic of the 21st century.银屑病、生物疗法与21世纪的大流行
Drugs Context. 2020 May 14;9. doi: 10.7573/dic.2020-4-10. eCollection 2020.
8
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control.生物制剂治疗的重度哮喘患者的 COVID-19 疫苗接种：安全性、耐受性及对疾病控制的影响
Vaccines (Basel). 2021 Aug 4;9(8):853. doi: 10.3390/vaccines9080853.
9
Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies.在 COVID-19 大流行期间，我们可以安全地在特应性皮炎患者中使用全身性治疗吗？对选定的常规和生物性全身性治疗的概述。
Expert Rev Clin Immunol. 2021 Jun;17(6):619-627. doi: 10.1080/1744666X.2021.1919511. Epub 2021 Apr 24.
10
Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study.新型冠状病毒肺炎对免疫介导的炎症性疾病患者的直接和间接影响：一项回顾性队列研究。
J Clin Med. 2021 May 28;10(11):2388. doi: 10.3390/jcm10112388.

引用本文的文献

1
Carotenoids as potential inhibitors of TNFα in COVID-19 treatment.类胡萝卜素作为 COVID-19 治疗中 TNFα 的潜在抑制剂。
PLoS One. 2022 Dec 27;17(12):e0276538. doi: 10.1371/journal.pone.0276538. eCollection 2022.
2
Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up.重症新型冠状病毒肺炎的成功治疗：1个月随访的白细胞介素-1和白细胞介素-6联合阻断治疗系列病例
Ther Adv Musculoskelet Dis. 2022 Sep 4;14:1759720X221116405. doi: 10.1177/1759720X221116405. eCollection 2022.
3
Immunomodulatory mechanisms of abatacept: A therapeutic strategy for COVID-19.阿巴西普的免疫调节机制：一种针对COVID-19的治疗策略。
Front Med (Lausanne). 2022 Jul 25;9:951115. doi: 10.3389/fmed.2022.951115. eCollection 2022.
4
Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.COVID-19 感染对既往呼吸道疾病的短期和长期影响。
Arch Bronconeumol. 2022 Apr;58 Suppl 1:39-50. doi: 10.1016/j.arbres.2022.03.011. Epub 2022 Apr 15.
5
Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target.新型冠状病毒肺炎中的内皮功能障碍：一种统一机制及潜在治疗靶点
Biomedicines. 2022 Mar 30;10(4):812. doi: 10.3390/biomedicines10040812.
6
A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable.一场大流行对全球肺部疾病的教训：可以预防加重。
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1271-1280. doi: 10.1164/rccm.202110-2389CI.
7
[COVID-19 in Youth and the Fifth Wave].[青少年中的新冠疫情与第五波疫情]
Arch Bronconeumol. 2022 Mar;58(3):213-214. doi: 10.1016/j.arbres.2021.08.019. Epub 2021 Sep 14.
8
Calcineurin Inhibitors and COVID-19.钙调神经磷酸酶抑制剂与新型冠状病毒肺炎
Reumatol Clin (Engl Ed). 2020 Sep 24;18(5):314-5. doi: 10.1016/j.reuma.2020.09.001.

本文引用的文献

1
Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.托珠单抗：从风湿病治疗领域到抗击新冠病毒肺炎这场多面病毒感染之战。
Expert Opin Biol Ther. 2020 Jul;20(7):717-723. doi: 10.1080/14712598.2020.1770222. Epub 2020 Jun 4.
2
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.我们应该在 COVID-19 中刺激还是抑制免疫反应？细胞因子和抗细胞因子干预。
Autoimmun Rev. 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4.
3
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.COVID-19 患者的依库珠单抗治疗：来自 ASL Napoli 2 Nord 真实经验的初步结果。
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047. doi: 10.26355/eurrev_202004_20875.
5
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.COVID-19、免疫系统反应、过度炎症和重新利用抗风湿药物。
Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. doi: 10.3906/sag-2004-168.
6
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
7
The Rheumatologist's Role in COVID-19.风湿病学家在COVID-19中的作用。
J Rheumatol. 2020 May 1;47(5):639-642. doi: 10.3899/jrheum.200334. Epub 2020 Mar 24.
8
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?COVID-19、细胞因子和免疫抑制：我们能从严重急性呼吸综合征中学到什么？
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342. doi: 10.55563/clinexprheumatol/xcdary. Epub 2020 Mar 22.
9
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
10
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.

Biologic Therapy in COVID-19.

作者信息

González-Gay Miguel A, Castañeda Santos, Ancochea Julio

机构信息

Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain.

Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

出版信息

Arch Bronconeumol. 2021 Jan;57:1-2. doi: 10.1016/j.arbres.2020.06.007. Epub 2020 Jun 26.

DOI:10.1016/j.arbres.2020.06.007
PMID:34629622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7318980/
Abstract
摘要